Mylan Launches HulioTM (Biosimilar Adalimumab) in Markets Across Europe
(WorldNews Netherlands)

HERTFORDSHIRE, Englandand PITTSBURGH, Oct. 19, 2018/PRNewswire / -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has initiated the commercial launch of HulioTM, a biosimilar to AbbVie`s Humira® (adalimumab), across major markets in Europe. The product, which is approved for all adalimumab indications, will be available to patients as soon as possible. Mylan PresidentRajiv Malik commented: `We`re proud of our strategic partnership with Fujifilm Kyowa Kirin Biologics and the strong collaboration of our science and technology teams to bring Hulio to market for patients. As the cost of healthcare continues to rise around the world, we know the important role that...